2022
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
Tolba K, Gandara D, Montesion M, Nabet B, Srivastava M, Albacker L, Redman M, Kozono D, Cummings C, Herbst R, Shames D, Fabrizio D. 584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab. 2022, a611-a611. DOI: 10.1136/jitc-2022-sitc2022.0584.Peer-Reviewed Original Research
2020
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.
Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyReasonable treatment optionMore side effectsLung cancer patientsCancer care settingsPatient-centered careTreatment decision processNational Quality ForumInhibitor therapyPatient-centric careCancer patientsTreatment optionsTreatment choicePost-intervention interviewsPatientsSide effectsPractice settingsQuality ForumSDM skillsHealthcare decisionsCareSDM processGreater improvementCliniciansTeam members
2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 2018, 9: 33995-34008. PMID: 30338041, PMCID: PMC6188056, DOI: 10.18632/oncotarget.26129.Peer-Reviewed Original ResearchLung cancerAdvanced non-small cell lung cancer (NSCLC) patientsNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsSubset of NSCLCWorse overall survivalCell lung cancerLung cancer patientsAnti-tumor effectsNovel therapeutic strategiesNSCLC cell linesTherapeutic paradigm shiftMAPK pathwayUnique therapeutic vulnerabilitiesOverall survivalCancer patientsClinical trialsLung adenocarcinomaKRAS/Therapeutic strategiesPharmacologic inhibitionTherapeutic vulnerabilitiesTherapeutic opportunitiesConcomitant targeting
2017
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.
Hellmann M, Ma J, Garon E, Hui R, Gandhi L, Soria J, Anderson K, Lubiniecki G, Piperdi B, Herbst R. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Journal Of Clinical Oncology 2017, 35: 77-77. DOI: 10.1200/jco.2017.35.7_suppl.77.Peer-Reviewed Original ResearchNon-small cell lung cancerLong-term survival ratesLong-term survivalAdvanced non-small cell lung cancerKEYNOTE-001KEYNOTE-010PD-L1Survival rateOverall survivalLong-term benefitsLong-term survival modelsNon-small cell lung cancer patientsCell lung cancer patientsPercentage of patientsSurvival modelsCell lung cancerLung cancer patientsTreat populationDocetaxel armPembrolizumab monotherapyParametric survival modelsCancer patientsLung cancerPatientsSubsequent independent validation
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original ResearchResearch Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research
Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clinical Cancer Research 2016, 22: 1907-1913. PMID: 26888828, PMCID: PMC4861174, DOI: 10.1158/1078-0432.ccr-16-0104.Peer-Reviewed Original ResearchConceptsTobacco use assessmentCancer patientsTobacco useClinical trialsTobacco dependence treatmentSecondhand smoke exposureNIH Clinical CenterClinical treatment trialsAlternative tobacco productsTobacco Use QuestionnaireTobacco use statusEffect of cessationClinical cancer researchTiming of assessmentCancer researchCessation approachesProtocol therapyStudy entrySmoke exposureTask ForceCigarette smokingAdverse outcomesTreatment trialsClinical centersDependence treatment
2015
Lung Cancer in the Era of Precision Medicine
Politi K, Herbst RS. Lung Cancer in the Era of Precision Medicine. Clinical Cancer Research 2015, 21: 2213-2220. PMID: 25979927, PMCID: PMC4505624, DOI: 10.1158/1078-0432.ccr-14-2748.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerClinical trialsBiomarker-driven clinical trialsLung cancer clinicEfficacy of immunotherapyLung cancer patientsLung cancer subtypesNovel therapeutic targetPrecision medicineFirst-generation drugsMetastatic diseaseCancer patientsEGFR mutationsCancer clinicActionable mutationsTherapeutic targetPatientsMolecular testingCancer subtypesImmune systemNew treatmentsMolecular subgroupsDrug resistanceMechanisms of sensitivityCancer
2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515: 563-567. PMID: 25428504, PMCID: PMC4836193, DOI: 10.1038/nature14011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkersChemokine CX3CL1Clinical ProtocolsCTLA-4 AntigenDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasmsTreatment OutcomeYoung AdultCirculating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Kowanetz M, Rabe C, Xiao Y, Wu Q, Koeppen H, Leddy C, Patel R, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst R, Desai R, Denker M, Ruppel J, Boe M, Nakamura R, Fu L, Sumiyoshi T, Mokatrin A, Shen X, Fine G, Chen D, Hegde P. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. Journal For ImmunoTherapy Of Cancer 2014, 2: p136. PMCID: PMC4288453, DOI: 10.1186/2051-1426-2-s3-p136.Peer-Reviewed Original ResearchEmerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway
Kris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway. Clinical Lung Cancer 2014, 15: 475. PMID: 25306384, DOI: 10.1016/j.cllc.2014.08.001.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerMET pathwayNon-small cell lung cancerCME activitiesProgression-free survivalLung cancer patientsLung cancer specialistsCare of patientsIndividualized treatment strategiesLung cancer mutationsClinical research advancesQuality of lifeCollection of diseasesFree survivalMedical oncologistsCancer patientsCancer specialistsPatient outcomesTreatment strategiesHealthcare cliniciansCancer cell mutationsPatientsTissue acquisitionMET expression119IN Novel Molecular Studies to Inform the Conduct of Oncology Clinical Trials: from Battle to Master Protocols
Herbst R. 119IN Novel Molecular Studies to Inform the Conduct of Oncology Clinical Trials: from Battle to Master Protocols. Annals Of Oncology 2014, 25: iv41. DOI: 10.1093/annonc/mdu317.1.Peer-Reviewed Original ResearchLung cancer patientsCancer patientsSquamous cell lung cancer patientsMaster protocolsMulticenter phase 2 trialCell lung cancer patientsNovel molecular studiesPhase 2 trialScreen failure rateOncology clinical trialsCause of deathEffective treatment regimensIdentification of therapiesClinical trial researchIndividual patient's cancerSystemic chemotherapyClinical characteristicsMetastatic diseaseMost patientsPerformance statusTreatment regimensMultiple therapiesClinical trialsAdaptive randomization designPatient's cancerAddressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients.
Pommerenke A, Alberg A, Gritz E, Cummings K, Brandon T, Croghan I, Dresler C, Herbst R, Leischow S, Marshall J, Toll B, Warren G. Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients. Journal Of Clinical Oncology 2014, 32: e17508-e17508. DOI: 10.1200/jco.2014.32.15_suppl.e17508.Peer-Reviewed Original ResearchVandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion
Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clinical Lung Cancer 2014, 15: 379-386. PMID: 24913066, PMCID: PMC4160385, DOI: 10.1016/j.cllc.2014.04.002.Peer-Reviewed Original ResearchConceptsRecurrent malignant pleural effusionCell lung cancer patientsMalignant pleural effusionLung cancer patientsCell lung cancerPleural effusionCancer patientsMedian timeCatheter placementLung cancerEastern Cooperative Oncology Group performance statusPoor overall median survivalEnd pointSingle-arm phase II clinical trialPhase II clinical trialIndwelling pleural catheterOverall median survivalPrimary end pointSecondary end pointsDaily oral doseWeeks of treatmentPleural fluid cytologyVEGF receptor inhibitorPleural fluid cytokinesEligible patients
2013
Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop
Balogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop. The Oncologist 2013, 19: 21-31. PMID: 24304712, PMCID: PMC3903060, DOI: 10.1634/theoncologist.2013-0230.Peer-Reviewed Original ResearchAddressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.
Warren G, Marshall J, Cummings K, Toll B, Gritz E, Hutson A, Dibaj S, Herbst R, Mulshine J, Hanna N, Dresler C. Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers. Journal Of Clinical Oncology 2013, 31: 1561-1561. DOI: 10.1200/jco.2013.31.15_suppl.1561.Peer-Reviewed Original ResearchTobacco cessation supportCancer patientsTobacco useOncology providersCessation supportTobacco cessationMedication optionsCancer outcomesClinical careTobacco cessation trainingMost respondentsCessation assistanceCessation trainingCessation treatmentCessation interventionsCessation practicesAdverse outcomesLung cancerCessation methodsTobacco assessmentInitial consultClinical OncologyPatientsPatient resistanceLack of timePractice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients
Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, Committee I. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients. Journal Of Thoracic Oncology 2013, 8: 543-548. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/jto.0b013e318288dc96.Peer-Reviewed Original ResearchConceptsCancer patientsTobacco useOncology providersPractice patternsClinical careInitial patient visitTobacco cessation activitiesLung cancer patientsTobacco cessation methodsCessation activitiesMedication optionsCessation assistanceCessation interventionsPoor outcomeSmoking cessationTobacco cessationCessation effortsCancer careLung cancerCessation methodsAffect OutcomesPatient visitsPhysician respondentsTobacco assessmentClinician educationAssessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement
Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS, Tobacco and Cancer W. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. Clinical Cancer Research 2013, 19: 1941-1948. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.ccr-13-0666.Peer-Reviewed Original ResearchConceptsTobacco useTobacco cessationCessation interventionsEvidence-based cessation interventionsTreatment-related toxicitySecond primary tumorsTobacco cessation interventionsQuality cancer careQuality of lifeAmerican AssociationCessation assistancePoor outcomeCancer careCancer patientsPrimary tumorOncology settingCancer recurrencePatientsTreatment efficacyTreatment settingsEvidence-based proceduresCancer leadCancerCancer progressionClinical infrastructure
2011
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 2011, 1: 44-53. PMID: 22586319, PMCID: PMC4211116, DOI: 10.1158/2159-8274.cd-10-0010.Peer-Reviewed Original ResearchConceptsLung cancer patientsCancer patientsNon-small cell lung cancer patientsLung Cancer Elimination (BATTLE) trialCell lung cancer patientsDisease control rateCore needle biopsy specimensLung cancer clinical trialsSpecific patient populationsLung cancer therapyNeedle biopsy specimensCancer clinical trialsRelevant molecular biomarkersKRAS patientsNSCLC patientsPatient populationRandomization periodControl rateLaboratory findingsLung cancerBiopsy specimensClinical trialsTargeted therapyBATTLE TrialIndividualized treatment
2010
Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling
Zoog SJ, Y. C, Kaplan‐Lefko P, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu C, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry Part A 2010, 77A: 849-860. PMID: 20623688, DOI: 10.1002/cyto.a.20940.Peer-Reviewed Original ResearchConceptsFine needle aspiratesDeath receptor 5Needle aspiratesNonsmall cell lung cancer patientsCell lung cancer patientsCaspase-3 activationLung cancer patientsTumor necrosis factorCaspase-3Tumor-bearing miceTumor cell deathReceptor therapyPharmacodynamic markersCancer patientsDrug exposureClinical trialsCaspase 3/7 activityNecrosis factorColo205 xenograftsClinical investigationReceptor 5FNA biopsyTumor typesPharmacological impactClinical setting
2009
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungDisease ProgressionDisease-Free SurvivalErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm Recurrence, LocalPrecision MedicinePredictive Value of TestsProteomeQuinazolinesConceptsNon-small cell lung cancer patientsCell lung cancer patientsAdvanced NSCLC patientsCombination of erlotinibLung cancer patientsToxic regimenNSCLC patientsPretreatment serumCancer patientsWorse outcomesProteomic classifierBlinded mannerPatientsErlotinibBevacizumabVeriStratSurvivalTreatmentRegimenProgressionSerum